KR20240152301A - 발프로산의 새로운 유사체 및 이를 이용한 의학적 치료 방법 - Google Patents

발프로산의 새로운 유사체 및 이를 이용한 의학적 치료 방법 Download PDF

Info

Publication number
KR20240152301A
KR20240152301A KR1020247024372A KR20247024372A KR20240152301A KR 20240152301 A KR20240152301 A KR 20240152301A KR 1020247024372 A KR1020247024372 A KR 1020247024372A KR 20247024372 A KR20247024372 A KR 20247024372A KR 20240152301 A KR20240152301 A KR 20240152301A
Authority
KR
South Korea
Prior art keywords
fibrosis
compound
pharmaceutical composition
compounds
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024372A
Other languages
English (en)
Korean (ko)
Inventor
토마스 펙스
요나스 페이제르슨 셀리에
Original Assignee
세레노 사이언티픽 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세레노 사이언티픽 에이비 filed Critical 세레노 사이언티픽 에이비
Publication of KR20240152301A publication Critical patent/KR20240152301A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247024372A 2021-12-20 2022-12-20 발프로산의 새로운 유사체 및 이를 이용한 의학적 치료 방법 Pending KR20240152301A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2118559.0 2021-12-20
GB2118559.0A GB2613900B (en) 2021-12-20 2021-12-20 Novel compounds and methods of use thereof
PCT/GB2022/053318 WO2023118846A1 (en) 2021-12-20 2022-12-20 Novel analogs of valproic acid and methods of medical treatment using the same

Publications (1)

Publication Number Publication Date
KR20240152301A true KR20240152301A (ko) 2024-10-21

Family

ID=84887257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024372A Pending KR20240152301A (ko) 2021-12-20 2022-12-20 발프로산의 새로운 유사체 및 이를 이용한 의학적 치료 방법

Country Status (11)

Country Link
US (1) US20250066282A1 (https=)
EP (1) EP4452917A1 (https=)
JP (1) JP2025500459A (https=)
KR (1) KR20240152301A (https=)
CN (1) CN118613464A (https=)
AU (1) AU2022422574A1 (https=)
CA (1) CA3242987A1 (https=)
GB (1) GB2613900B (https=)
IL (1) IL313669A (https=)
MX (1) MX2024007654A (https=)
WO (1) WO2023118846A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2644641A (en) * 2024-09-24 2026-04-29 Cereno Scient Ab New methods
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension
GB2644610A (en) * 2024-09-27 2026-04-22 Cereno Scient Ab New methods
WO2026068552A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071554A1 (en) * 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
US20100143507A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
RU2760304C2 (ru) * 2016-04-08 2021-11-23 Серено Сайентифик Аб Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение

Also Published As

Publication number Publication date
GB2613900A (en) 2023-06-21
CN118613464A (zh) 2024-09-06
IL313669A (en) 2024-08-01
CA3242987A1 (en) 2023-06-29
MX2024007654A (es) 2024-07-04
GB2613900B (en) 2024-01-17
AU2022422574A1 (en) 2024-07-18
EP4452917A1 (en) 2024-10-30
US20250066282A1 (en) 2025-02-27
WO2023118846A1 (en) 2023-06-29
JP2025500459A (ja) 2025-01-09

Similar Documents

Publication Publication Date Title
KR20240152301A (ko) 발프로산의 새로운 유사체 및 이를 이용한 의학적 치료 방법
JP4775259B2 (ja) アニリン誘導体
KR20240008882A (ko) 약학적 활성 화합물로서 레조르시놀 유도체 및 이의 제조방법
KR100400507B1 (ko) 치환 피롤리딘 히드록사메이트 메탈로프로테아제 억제제
JP2000516251A (ja) １，３―ジヘテロ環式メタロプロテアーゼ阻害剤類
US8394807B2 (en) Quinazoline inhibitors of BACE 1 and methods of using
CN102036956A (zh) 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法
RU2753607C2 (ru) Способы лечения острого повреждения почек
PT1369419E (pt) Composto de n-fenilarilsulfonamida, fármaco contendo o composto como ingrediente activo, produtos intermédios para a produção do composto e processos para a produção do composto
WO2021243018A1 (en) Substituted indoles with inhibitory activity
HRP20050517A2 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
US8859590B2 (en) Inhibitors of BACE1 and methods for treating Alzheimer's disease
JP2009539838A (ja) マクロファージ転位阻害因子阻害剤としてのオキシム誘導体
KR101061764B1 (ko) 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2024089159A1 (en) Main protease inhibitors
WO2016006593A1 (ja) 新規ベンズオキサジン誘導体及びこれを含有する医薬
CN100560568C (zh) 环酰亚胺类肽金属蛋白酶抑制剂及其应用
JPWO2015046405A1 (ja) 鎮痛剤
TW201700474A (zh) 新的５型磷酸二酯酶抑制劑及其醫藥應用
AU2023376662B2 (en) Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell disease
CN115557898B (zh) 一种咪唑类化合物、其中间体及应用
US20240327376A1 (en) Picolinamide compounds as selective phd1 inhibitors, compositions, and methods of use
JP5099692B2 (ja) 新規トリハロメチオニン誘導体及びそれを含む医薬
EA050218B1 (ru) Производные 6-метилурацила, обладающие антихолинэстеразной активностью, и их применение
WO2022135514A1 (zh) 多取代的尿嘧啶衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000